NATCO Pharma Limited
NSE: NATCOPHARM BSE: NATCOPHARM
Prev Close
1002.7
Open Price
1015
Volume
2,029,982
Today Low / High
1012.7 / 1050.95
52 WK Low / High
726.8 / 1059
Range
987 - 1,091
Prev Close
1002.2
Open Price
1021.95
Volume
86,977
Today Low / High
1014 / 1051.2
52 WK Low / High
660.05 / 1340.45
Range
987 - 1,091
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1039.2 (target range: 987 - 1,091), reflecting a change of 36.5 (3.64017%). On the BSE, it is listed at 1039.45 (target range: 987 - 1,091), showing a change of 37.25 (3.71682%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
NATCO Pharma Limited Graph
NATCO Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NATCO Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,039.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,039.45 | 1,049.84 | 944.86 - 1,154.83 |
| 1,060.24 | 848.19 - 1,272.29 | ||
| 1,070.63 | 749.44 - 1,391.82 | ||
| Bearish Scenario | 1,039.45 | 1,029.06 | 926.15 - 1,131.96 |
| 1,018.66 | 814.93 - 1,222.39 | ||
| 1,008.27 | 705.79 - 1,310.75 |
Overview of NATCO Pharma Limited
ISIN
INE987B01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,450,675
Market Cap
171,273,813,188
Last Dividend
5
Official Website
IPO Date
1996-01-01
DCF Diff
-1,183.99
DCF
2,067
Financial Ratios Every Investor Needs
Stock Dividend of NATCOPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-18 | February 18, 26 | 1.5 | 1.5 | 2026-02-18 | 2026-02-26 | |
| 2025-11-20 | November 20, 25 | 1.5 | 1.5 | 2025-11-20 | 2025-11-28 | |
| 2025-08-19 | August 19, 25 | 2 | 2 | 2025-08-19 | 2025-08-26 | |
| 2025-02-18 | February 18, 25 | 1.5 | 1.5 | 2025-02-18 | 2025-03-14 | |
| 2024-11-27 | November 27, 24 | 1.5 | 1.5 | 2024-11-27 | 2024-12-04 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,431.90 Cr | 727.40 Cr | 3,704.50 Cr | 0.8359 | 104.00 Cr | 0.00 Cr | 3,000.30 Cr | 1,885.40 Cr | 105.26 | 2,144.20 Cr | 0.4254 |
| 2024-03-31 | 4,002.00 Cr | 748.70 Cr | 3,253.30 Cr | 0.8129 | 121.10 Cr | 0.00 Cr | 2,596.20 Cr | 1,388.30 Cr | 77.34 | 1,750.60 Cr | 0.3469 |
| 2023-03-31 | 2,708.50 Cr | 654.40 Cr | 2,054.10 Cr | 0.7584 | 89.20 Cr | 0.00 Cr | 1,491.60 Cr | 715.30 Cr | 39.18 | 966.90 Cr | 0.2641 |
| 2022-03-31 | 1,946.20 Cr | 584.50 Cr | 1,361.70 Cr | 0.6997 | 168.20 Cr | 467.90 Cr | 693.00 Cr | 170.00 Cr | 9.32 | 260.00 Cr | 0.0873 |
| 2021-03-31 | 2,056.10 Cr | 531.80 Cr | 1,524.30 Cr | 0.7414 | 142.50 Cr | 429.60 Cr | 931.10 Cr | 440.90 Cr | 24.20 | 606.60 Cr | 0.2144 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,176.00 Cr | 8,630.80 Cr | 1,018.50 Cr | 7,607.0000 Cr | 279.40 Cr | -1,896.60 Cr | 765.80 Cr | 2,657.30 Cr | 0.00 Cr | 0.00 Cr | 335.10 Cr | 943.5000 Cr |
| 2024-03-31 | 70.40 Cr | 6,906.30 Cr | 1,053.20 Cr | 5,853.1000 Cr | 386.10 Cr | 315.70 Cr | 791.70 Cr | 2,435.00 Cr | 0.00 Cr | 4.00 Cr | 97.30 Cr | 972.8000 Cr |
| 2023-03-31 | 131.90 Cr | 5,657.40 Cr | -3,480.00 Cr | 4,873.8000 Cr | 176.10 Cr | 34.80 Cr | 808.90 Cr | 2,303.40 Cr | 112.90 Cr | 1.70 Cr | -925.90 Cr | 683.1000 Cr |
| 2022-03-31 | 111.10 Cr | 5,109.10 Cr | 845.50 Cr | 4,263.6000 Cr | 432.00 Cr | 320.90 Cr | 862.00 Cr | 2,308.40 Cr | 87.70 Cr | 1.30 Cr | 108.90 Cr | 710.4000 Cr |
| 2021-03-31 | 25.80 Cr | 4,791.90 Cr | 668.50 Cr | 4,121.6000 Cr | 283.90 Cr | 258.10 Cr | 910.40 Cr | 2,237.20 Cr | 1.30 Cr | 1.10 Cr | -625.00 Cr | 525.6000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,696.8000 Cr | -1,414.5000 Cr | -210.7000 Cr | 1,428.0000 Cr | 49.6000 Cr | 120.0000 Cr | -511.6000 Cr | 1,885.4000 Cr | -89.2000 Cr | -107.8000 Cr | -65.3000 Cr |
| 2024-03-31 | 1,211.6000 Cr | -1,032.7000 Cr | -246.9000 Cr | 872.2000 Cr | -61.5000 Cr | 70.4000 Cr | -339.4000 Cr | 1,388.3000 Cr | 197.8000 Cr | -170.8000 Cr | 42.4000 Cr |
| 2023-03-31 | 849.1000 Cr | -477.1000 Cr | -363.0000 Cr | 643.5000 Cr | 20.8000 Cr | 131.9000 Cr | -205.6000 Cr | 861.9000 Cr | -239.0000 Cr | -100.4000 Cr | 19.1000 Cr |
| 2022-03-31 | 46.5000 Cr | -5.3000 Cr | 34.8000 Cr | -196.2000 Cr | 85.3000 Cr | 111.1000 Cr | -242.7000 Cr | 202.2000 Cr | -2.4000 Cr | -82.2000 Cr | 56.4000 Cr |
| 2021-03-31 | 298.8000 Cr | -103.3000 Cr | -185.7000 Cr | 44.2000 Cr | 6.0000 Cr | 25.8000 Cr | -254.6000 Cr | 579.6000 Cr | -48.4000 Cr | -113.9000 Cr | -240.2000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 647.30 Cr | 133.10 Cr | 514.20 Cr | 0.7944 | 112.50 Cr | 151.50 Cr | 8.46 | 216.80 Cr | 0.2340 |
| 2025-09-30 | 1,363.00 Cr | 169.70 Cr | 1,193.30 Cr | 0.8755 | 526.80 Cr | 518.40 Cr | 28.94 | 679.20 Cr | 0.3803 |
| 2025-06-30 | 1,328.90 Cr | 233.00 Cr | 1,095.90 Cr | 0.8247 | 513.40 Cr | 480.70 Cr | 26.84 | 632.70 Cr | 0.3617 |
| 2025-03-31 | 1,223.40 Cr | 286.80 Cr | 936.60 Cr | 0.7656 | 667.50 Cr | 406.60 Cr | 22.70 | 499.70 Cr | 0.3324 |
| 2024-12-31 | 474.80 Cr | 82.80 Cr | 392.00 Cr | 0.8256 | 250.40 Cr | 133.00 Cr | 7.43 | 36.80 Cr | 0.2801 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 103.50 Cr | 3,973.30 Cr | 4,076.80 Cr | 1,729.10 Cr | 818.00 Cr | 6,966.70 Cr | 2,692.30 Cr | 10,430.10 Cr | 1,775.90 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2,496.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,612.30 Cr |
| 2025-03-31 | 2,176.00 Cr | 2,687.60 Cr | 2,496.80 Cr | 1,256.00 Cr | 765.80 Cr | 5,270.00 Cr | 2,657.30 Cr | 8,630.80 Cr | 1,018.50 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,463.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,156.80 Cr |
| 2024-09-30 | 104.60 Cr | 2,358.80 Cr | 2,463.40 Cr | 1,445.80 Cr | 774.60 Cr | 5,001.50 Cr | 2,538.20 Cr | 8,244.70 Cr | 1,087.90 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 480.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 406.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 133.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 677.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 668.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-11-26 | November 26, 15 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Gender: Not Specified
Year Born: 1952
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1958
Gender: male
Year Born: 1977
Gender: male
Year Born:
Gender: male
Year Born: 1945
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born:
FAQs about NATCO Pharma Limited
The CEO is Rajeev Nannapaneni.
The current price is ₹956.25.
The range is ₹726.8-1059.
The market capitalization is ₹17,127.38 crores.
The dividend yield is 0.52%.
The P/E ratio is 11.00.
The company operates in the Healthcare sector.
Overview of NATCO Pharma Limited (ISIN: INE987B01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹17,127.38 crores and an average daily volume of 1,450,675 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.